NEW YORK — Startup Deep Longevity said on Tuesday that it has closed a Series A round of financing and formed a partnership with genome sequencing company Human Longevity.
Spun out of Insilico Medicine in January, Deep Longevity is developing artificial intelligence-based systems to track aging based on a variety of molecular, cellular, and other biomarkers and datapoints. Its offerings include so-called aging clocks designed to provide measures of biological age.